Cited by 803Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 173 of the 176 references it cites were found in a registry or an index.

Parkinson’s disease: genetics and pathogenesis

Shulman, Joshua M., De Jager, Philip L., Feany, Mel B.·2011·Annual Review of Pathology: Mechanisms of Disease

DOI 10.1146/annurev-pathol-011110-130242

Open this paper in CoChat — free account

Abstract

Recent investigation into the mechanisms of Parkinson's disease (PD) has generated remarkable insight while simultaneously challenging traditional conceptual frameworks. Although the disease remains defined clinically by its cardinal motor manifestations and pathologically by midbrain dopaminergic cell loss in association with Lewy bodies, it is now recognized that PD has substantially more widespread impact, causing a host of nonmotor symptoms and associated pathology in multiple regions throughout the nervous system. Further, the discovery and validation of PD-susceptibility genes contradict the historical view that environmental factors predominate, and blur distinctions between familial and sporadic disease. Genetic advances have also promoted the development of improved animal models, highlighted responsible molecular pathways, and revealed mechanistic overlap with other neurodegenerative disorders. In this review, we synthesize emerging lessons on PD pathogenesis from clinical, pathological, and genetic studies toward a unified concept of the disorder that may accelerate the design and testing of the next generation of PD therapies.

Integrity signals

Registry

Crossref · 10.1146/annurev-pathol-011110-130242

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's Disease
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836

Show all 176 references

Research works printed but not linked: 4

Parkinson J, 1817, An Essay on the Shaking Palsy
Priyadarshi A, 2000, Neurotoxicology, 21, 435
Gilks W, 2005, Lancet, 365, 415
Nichols WC, 2005, Lancet, 365, 410

Sorted by citations

Items 601–700 of 803

Molecular Chaperones in Neurodegeneration
Pandey, M., Nabi, J., Tabassum, N., Pottoo, F. H., Khatik, R., & Ahmad, N. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch014 · Cited by 4
Molecular Mechanisms of Neurological Disease
Gireud, M., Sirisaengtaksin, N., & Bean, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397179-1.00021-x · Cited by 5
Parkinson’s Disease
Beier, E. E., & Richardson, J. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00013-3 · Cited by 4
Translational research on disease‐modifying therapies for neurodegenerative diseases
Katsuno, M., Watanabe, H., Tanaka, F., & Sobue, G. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.7 · Cited by 4
GAMMA-PD: Graph-Based Analysis of Multi-Modal Motor Impairment Assessments in Parkinson’s Disease
Nerrise, F., Heiman, A., & Adeli, E. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-83243-7_6 · Cited by 4
Deficiency of SCAMP5 causes Parkinson’s disease due to loss of dopamine neurons
Liu, H., Ge, S., Liu, Z., Hou, M., Jia, W., Li, J., Wang, G., Sun, N., Wang, X., & Zhang, X. (2025) · Human Genetics · doi:10.1007/s00439-025-02783-5 · Cited by 3
Estimulación Transcraneal de Corriente Directa en Parkinson - Revisión Sistemática
Vega, D. M. P., & da Costa, M. L. G. (2013) · Revista Neurociências · doi:10.4181/rnc.2013.21.841.8p · Cited by 3
Nano-biosensors for Diagnosing Infectious and Lifestyle-Related Disease of Human: An Update
Padma, S., Chakraborty, P., & Mukherjee, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-7130-3_4 · Cited by 5
Mechanistic insights into condensate formation of human liver-type phosphofructokinase by stochastic modeling approaches
Kang, H.-W., Nguyen, L., An, S., & Kyoung, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-69534-w · Cited by 4
Stem Cell Approaches for Treatment of Neurodegenerative Diseases
Anand, S. (2014) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.1000126 · Cited by 3
[Autophagy pathways and key drug targets in Parkinson's disease].
Ouyang, L., Zhang, L., & Liu, B. (2016) · PubMed · Cited by 3
A Possible Mechanism for the Propagation of Pathological Proteins in Parkinson’s Disease
(2015) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000006 · Cited by 3
The effect of directional social cues on saccadic eye movements in Parkinson’s disease
Koçoğlu, K., Akdal, G., Çolakoğlu, B. D., Çakmur, R., Sharma, J. C., Ezard, G., Hermens, F., & Hodgson, T. L. (2021) · Experimental Brain Research · doi:10.1007/s00221-021-06034-7 · Cited by 3
The Role of Inflammasomes in the Pathogenesis of Neurodegenerative Diseases
Shevchuk, D. V., Abramova, A. A., & Zakharova, M. N. (2022) · Neurochemical Journal · doi:10.1134/s1819712422030114 · Cited by 3
A computational study on structural and functional consequences of nsSNPs in human dopa decarboxylase
Kumar, S. B., Girish, A., Sutar, S., Premanand, S. A., Garg, V., Yadav, A. K., Shukla, R., Murthy, T. P. K., & Singh, T. R. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2301517 · Cited by 3
Cambios neuropsicológicos asociados a estimulación cerebral profunda en enfermedad de Parkinson: Revisión Teórica
Mejía, Ó. M. A., Soto, C. A., & Esguerra, M. (2011) · Dialnet (Universidad de la Rioja) · doi:10.14349/sumapsi2011.795 · Cited by 3
Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer’s and Parkinson’s Diseases
Santiago-Lopez, A. J., Hovell, C. M., Lee, H., & Kim, Y. (2015) · Biosystems & biorobotics · doi:10.1007/978-3-319-21813-7_13 · Cited by 3
Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.
Xing, L., Wang, D., Wang, L., Lan, W., & Pan, S. (2015) · PubMed Central · Cited by 3
Parkinson’s Disease: Diagnosis, Motor Symptoms and Non-motor Features
Jankovic, J. J. (2013) · doi:10.2217/9781780843391 · Cited by 4
La taille de l’axone est un facteur majeur influençant la dépense énergétique et la vulnérabilité des neurones dopaminergiques dans la maladie de Parkinson
Giguère, N., & Trudeau, L. (2016) · médecine/sciences · doi:10.1051/medsci/20163204010 · Cited by 3
Altered Expression ofEPOMight Underlie Hepatic Hemangiomas inLRRK2Knockout Mice
Wu, B., Xiao, K., Zhang, Z., & Ma, L. (2016) · BioMed Research International · doi:10.1155/2016/7681259 · Cited by 3
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease
Florczak‐Wyspianska, J., Różycka, A., Łukasz, W., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2017) · DNA and Cell Biology · doi:10.1089/dna.2016.3569 · Cited by 3
Cold flow model testing of the HYTORT process retort design
Rex, R. C., Janka, J. C., & Knowlton, T. M. (1984) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 3
Prevention of neurodegenerative disorders by nutraceuticals
Pistollato, F., & Sachana, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821038-3.00002-1 · Cited by 3
Toward Personalized Cell Therapies by Using Stem Cells
Isobe, K.-I., Cheung, H. S., & Wu, J. (2012) · BioMed Research International · doi:10.1155/2012/172564 · Cited by 3
Structural Variation and the Expanding Genomic Architecture of Parkinson Disease
Shulman, J. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4263 · Cited by 3
Self-citation
Phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregationPreprint
Dutta, S., Hensel, J. A., Scott, A. N., Mohallem, R., Rossitto, L.-A. M., Khan, H. F., Diehl, L. A., Johnson, T., Colon, B. D., Gold, J. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634820 · Cited by 3
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease
Martínez‐Martín, P., Hernandez, B., & Ricart, J. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2012.12.002 · Cited by 2
Current methods for studying intracellular liquid-liquid phase separation
Titus, A. R., & Kooijman, E. E. (2021) · Current topics in membranes · doi:10.1016/bs.ctm.2021.09.003 · Cited by 2
Gut–Brain Cross Talk: Microbiome and Micronutrients
Khalil, N. A., & Sarbini, S. R. (2022) · Nutritional neurosciences · doi:10.1007/978-981-16-6467-0_3 · Cited by 2
Computer-Aided Identification of Cholinergic and Monoaminergic Inhibitory Flavonoids from Hibiscus sabdariffa L.
Falade, A. O., Adewole, K. E., Gyebi, G. A., & Ishola, A. A. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163819666220525101039 · Cited by 2
Chrysin supplementation mitigated neurobehavioral changes in a animal model of Parkinson’s disease: Influence on TH+ neurons
de Gomes, M. G., Goes, A. T. R., Fabbro, L. D., Souza, L. C., Ladd, A. A. B. L., Ladd, F. V. L., Boeira, S. P., & Jessé, C. R. (2022) · Learning and Motivation · doi:10.1016/j.lmot.2022.101847 · Cited by 2
Carnosic acid attenuated cytochrome c release through the mitochondrial structural protein Mic60 by PINK1 in SH-SY5Y cells
Lin, C., Huang, Y.-C., Wu, C., Wu, H.-T., Fu, R., & Tsai, C.-W. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113636 · Cited by 2
A NETWORK PHARMACOLOGY-BASED DRUG REPURPOSING STUDY OF LEVETIRACETAM UNCOVERS ITS INTERACTION WITH MULTI-DRUG TARGETS IN PARKINSON'S DISEASE
PANDEY, N., Karthik, V., Selva, P., & Hazeena, P. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i6.51887 · Cited by 2
Pharmacotherapy of PD and related movements disorders and their limitations
Soliman, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16128-5.00002-5 · Cited by 2
Autophagy related genes polymorphisms in Parkinson’s Disease; A systematic review of literature
Yousefi, P., Ghadirian, S., Mobedi, M., Jafarzadeh, M., Alirezaei, A., Gholami, A., & Tabibzadeh, A. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100312 · Cited by 2
Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets
Godde, K., Raut, S. P., Rokde, R., & Zatke, L. (2025) · Geriatric Care · doi:10.4081/gc.2025.13936 · Cited by 2
Probing the Neuro-psychological Changes Observed with the Administration of COVID-19 Drugs
Chatterjee, I., & Bansal, V. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221223112247 · Cited by 2
The utility and caveat of split-GAL4s in the study of neurodegeneration
Stickley, L., Koch, R., & Nagoshi, E. (2023) · Fly · doi:10.1080/19336934.2023.2192847 · Cited by 2
An Evolutionary Biology Approach to Understanding Neurological Disorders
Aziz, A., Ilievska, J., Paul, R., & Naomi, E. (2012) · InTech eBooks · doi:10.5772/37919 · Cited by 2
Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes españoles con enfermedad de Parkinson
Martínez‐Martín, P., Hernandez, B., & Ricart, J. (2013) · Neurología · doi:10.1016/j.nrl.2012.12.008 · Cited by 2
Alternative Splicing and Nonsense Mediated Decay in Mitochondrial Complex-I Biogenesis and its Implication in Human Diseases
Panelli, D., & Papa, P. (2013) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.s3-006 · Cited by 2
Clinical Need and Rationale for Multi-Target Drugs in Psychiatry
Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2
Cerebrospinal fluid biomarkers for neurodegenerative disorders
Videira, R. M. A. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
A graph-clustering approach to search important molecular markers and pathways of Parkinson’s disease
Diao, B., Liu, Y., Zhang, Y., & Xu, G. (2011) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb.9000007 · Cited by 2
Air Pollution Exposure Studies Related to Human Health
Singh, N. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-981-15-3481-2_7 · Cited by 2
Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine- Induced Parkinsonism in Male Rats
Razaghi, R., Piri, H., Jafari, H., Rastgoo, N., Hosseini, M. A., & Haghdoost-Yazdi, H. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.671.3 · Cited by 2
Machine Learning Neuroprotective Strategy Reveals a Unique Set of Parkinson Therapeutic Nicotine Analogs
Rojas-Rodríguez, F., Morantes, C., Pinzón, A. M., Barreto, G. E., Cabezas, R., Mariño‐Ramírez, L., & González, J. (2020) · The Open Bioinformatics Journal · doi:10.2174/1875036202013010001 · Cited by 2
RNA therapeutics for neurological disease
Nguyen, L. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.005 · Cited by 2
Protective Effect of Medicinal Plants on Neuron Degeneration Diseases and Controversial Predictive Diagnosis
Elalfy, M. M. (2019) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2019.02.000599 · Cited by 2
Kinetic Program and Functional Status in Patients with Parkinson's Disease.
Trăistaru, R., Kamal, D., Matei, D., Rogoveanu, O. C., & Trașcă, D.-M. (2016) · Europe PMC (PubMed Central) · doi:10.12865/chsj.42.01.08 · Cited by 2
Amyloid fibrils are nanoparticles that target lysosomes.
Jakhria, T. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University) · Cited by 2
Electrophysiological and motoric effects of galvanic vestibular stimulation in normal and Parkinson's disease subjects
Kim, D. J. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0073863 · Cited by 4
Measurement and evaluation of biomarkers of oxidative stress, inflammation, haemorheology and whole blood antioxidant capacity in healthy, rheumatoid arthritis and Parkinson’s disease populations
Hughes, D. L. (2018) · Charles Sturt University Research Output (CRO) · Cited by 2
SIRT6 regulates protein synthesis and folding through nucleolar remodelingPreprint
Toiber, D., Stein, D., Portillo, M., Kaluski-Kopatch, S., Stein, D., Lachberg, Y., Eremenko, E., Smirnov, D., Einav, M., Khrameeva, E. E., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4215918/v1 · Cited by 2
At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products
Asiago, J. M., Doyle, T. B., Mishra, V. R., Jacquet, A. D. R., & Rochet, J. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622888-00325 · Cited by 1
The Influence of Dopaminergic Medication on Regularity and Determinism of Gait and Balance in Parkinson’s Disease: A Pilot Analysis
Workman, C. D., & Thrasher, T. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216485 · Cited by 1
Integrated Microfluidic Hydrogel‐Enhanced Microwell Array for Uniform Self‐Assembly, Long‐Term Culture, and Neural Differentiation of Mesenchymal Stem Cell Spheroids
Bi, W., Cai, S., Zhou, L., Zheng, J., Cui, Y., Li, Y., Liu, S., Chen, H., Sha, S., Li, J., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202501265 · Cited by 1
A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson’s disease motor symptoms
An, X., Su, L., Qi, Y., Shen, B., Gan, L., Ji, J., Wang, J., & Su, H. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01187-6 · Cited by 1
Longitudinal Repeatome Remodeling in Peripheral Blood Following Parkinson’s Disease Diagnosis
Kulski, J. K., & Kõks, S. (2026) · Genes · doi:10.3390/genes17050577 · Cited by 1
Conformation and electronic structure of Carbidopa. A QM/MD study
Sukker, G. M., Wazzan, N. A., Ahmed, A. A., & Hilal, R. (2015) · Journal of Theoretical and Computational Chemistry · doi:10.1142/s0219633616500024 · Cited by 1
Previous Injury and Chronic Pain are Associated with Side of Onset in Parkinson’s Disease
Tekin, I. (2015) · Journal of Neurology and Neurobiology · doi:10.16966/2379-7150.109 · Cited by 1
Geriatric Anesthesia: Age-Dependent Changes in the Central and Peripheral Nervous Systems
Doshi, A. K., Cabeza, R. E. L., & Berger, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-66878-9_10 · Cited by 1
MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons
Xu, Y., Tang, J., Liu, C., Zhao, C., Cao, S., Yu, H., Chen, Z., & Xie, M. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.02.004 · Cited by 1
A systematic review of the parasites (Acanthocephala) of the domestic waterfowl
Rzayev, F. H. O., & Qasımov, E. K. O. (2021) · doi:10.36719/2707-1146/2021/1/1 · Cited by 1
New Magnetic Resonance Imaging Biomarkers Advance the Characterization of Parkinson Disease
Ziegler, D. A., & Corkin, S. (2013) · touchREVIEWS in Neurology · doi:10.17925/usn.2013.09.01.8 · Cited by 1
Asymmetric Presynaptic Depletion of Dopamine Neurons in a Drosophila Model of Parkinson’s Disease
Zhang, J., Lentz, L., Goldammer, J., Iliescu, J., Tanimura, J., & Riemensperger, T. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108585 · Cited by 1
Parkinson's Disease models of Caenorhabditis elegans to study mechanism of action of Ayurvedic nootropics
Jalagam, A., & Godbole, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00010-7 · Cited by 1
Effects of movement congruence on motor resonance in early Parkinson’s disease
Gentile, E., Brunetti, A., Ricci, K., Vecchio, E., Santoro, C., Sibilano, E., Bevilacqua, V., Iliceto, G., Craighero, L., & de Tommaso, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-42112-2 · Cited by 1
Zero-length crosslinking: A breakthrough approach for evaluating target engagement in α-synuclein immunotherapy
Rochet, J., Qi, W., & Kirik, D. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2024.100036 · Cited by 1
Compositions and methods for treatment of Parkinson's disease: a patent evaluation of WO2011/102847A1
Chiurchiù, V., Maccarrone, M., & Orlacchio, A. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.655269 · Cited by 1
Prevention of Neurodegenerative Disorders by Nutraceuticals
Pistollato, F., & Sachana, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802147-7.00002-4 · Cited by 1
Genetic Factors in Environmentally Induced Disease
Greenamyre, J. T., & Barrett, P. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00002-9 · Cited by 1
Huntington Disease, Parkinson Disease, and Other Neurodegenerative Diseases
Möller, T. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199794591.003.0065 · Cited by 1
LRRK2 Signalling Pathways in Parkinson’s Disease
Zhang, J. (2019) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2019.02.000540 · Cited by 1
The serum level of cystatin C does not predict dopaminergic cell death in substantia nigra, evidence from 6-hydroxydopamine-induced animal model of Parkinson's disease
Sarbazi-Golezari, A., Haghdoost-Yazdi, H., & Minaei, A. (2020) · Physiology and Pharmacology · doi:10.32598/ppj.24.2.10 · Cited by 1
RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
Sarbazi-Golezari, A., & Haghdoost-Yazdi, H. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00868-4 · Cited by 1
Retracted
Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases
Grivennikov, I. A., & Tarantul, V. Z. (2021) · Neurochemical Journal · doi:10.1134/s181971242104005x · Cited by 1
Parkinson's disease and a dopamine-derived neurotoxin, 3,4-Dihydroxyphenylacetaldehyde
Eckert, L. L. (2012) · doi:10.17077/etd.5twcno7l · Cited by 1
Immunotherapeutics for Neurological Disorders
Messer, A. C., MANLEY, K. M., & Lemere, C. A. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch40 · Cited by 1
Molecular mechanisms of cortical degeneration in Parkinson disease
Shulman, J. M., & Schneider, J. A. (2012) · Neurology · doi:10.1212/wnl.0b013e31827040c6 · Cited by 1
Self-citation
Parkinson’s disease : the prodromal phase and consequences with respect to working life
Gustafsson, H. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Characterization of Vesicular Monoamine Transporter 2 and its role in Parkinson's Disease Pathogenesis using Drosophila
Tito, A. J., & Zhang, S. (2016) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Genetic Models of Parkinson’s Disease
Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1
Novel computational deep learning strategy for neuroprotection identification reveals unique set of nicotine analogs as potential therapeutic compounds against Parkinson’s diseasePreprint
Rojas-Rodríguez, F., Morantes, C., Pinzón, A. M., Barreto, G. E., Cabezas, R., Mariño‐Ramírez, L., & González, J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/740050 · Cited by 1
Categorization Model for Parkinson's Disease Occurrence and Severity Prediction
Shrivastava, P. K., Chaturvedi, A., Kamble, M., & Jain, M. (2022) · doi:10.1002/9781119884392.ch8 · Cited by 1
Modulating the aggregation of alpha-synuclein and prion protein with small molecules.
Fonseca‐Ornelas, L. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5964 · Cited by 1
M A T E R I A L S I İNTERNATİONAL SCIENTIFIC CONFERENCE ON "FUNDAMENTALS OF MEDICAL SCIENCE"
(2021) · doi:10.36719/2707-1146/2021/01/01 · Cited by 1
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in DrosophilaPreprint
Liu, W., Lim, K., & Tan, E. (2022) · Research Square · doi:10.21203/rs.3.rs-1706792/v1 · Cited by 1
miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A
Markham, B. N., Ramnarine, C., Kim, S., Grever, W. E., Soto-Beasley, A. I., Heckman, M. G., Ren, Y., Osborne, A. C., Kehili, M., Bhagwate, A. V., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00029-w
Tremulous Jaw Movements Induced by the VMAT2 Inhibitor Tetrabenazine
Podurgiel, S. J. (2012) · OpenCommons - UConn (University of Connecticut)
Verbal Fluency in Parkinson`s disease: neuroanatomical correlates and functional networks modulated by noninvasive brain stimulation
Pereira, J. B. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Cognition in healthy aging and Parkinson's disease : structural and functional integrity of neural circuits
Ziegler, D. A. (2011)
Effektivität der telemedizinischen Behandlung des fortgeschrittenen Morbus Parkinson
Doletschek, C. M. (2015) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15459
Occupational exposure to extremely low frequency magnetic fields and the risk of chronic diseases
Koeman, T. (2014) · Utrecht University Repository (Utrecht University)
Progress Towards Understanding Of Mechanisms Of Action Of Potent Multifunctional Disease Modifying Therapeutics For Parkinson's Disease & Investigating The Methamphetamine-Induced Striatal Microglia Activation.
Shah, M. M. (2013) · Human Biology
A D. melanogaster parkin mutant larval model of Parkinson's Disease
Vincent, A. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
A flow cytometry-based method for gene expression profiling of CNS cell types
Luo, T. (2014) · DSpace@MIT (Massachusetts Institute of Technology)
Microdevices for Isolating Single Axons for the Study of Axonal Transport in Dopaminergic Neurons
Lu, X. (2013) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7ft8j1n
Hoarding Behavior and Hoarding Disorder
Tompkins, M. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-1432-6_2

Authors: Shulman, J. M., De Jager, P. L., & Feany, M. B.
Affiliations: Broad Institute (US)
Departments of Neurology, Boston, Massachusetts 02115;
Departments of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115;
ORCID: Shulman, Joshua M.
Venue: Annual Review of Pathology: Mechanisms of Disease
Publisher: Annual Reviews
Published: 2011-02-28
Volume: 6
Issue: 1
Pages: 193-222
ISSN: 1553-4006 (ISSN-L)
1553-4014
DOI: 10.1146/annurev-pathol-011110-130242
OpenAlex: W2129917779
Cited by: 801
References: 176
Citations by year: 2026: 10 · 2025: 21 · 2024: 42 · 2023: 34 · 2022: 64 · 2021: 64 · 2020: 46 · 2019: 59 · 2018: 54 · 2017: 59 · 2016: 74 · 2015: 64 · 2014: 56 · 2013: 65 · 2012: 52
FWCI: 8.22
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Pathology Mechanisms of Disease (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: Parkinson's disease, susceptibility genes, pathogenesis, dopaminergic neuron loss, Lewy bodies, non-motor symptoms, animal models, neurodegeneration, molecular pathways
MeSH terms: Animals, Humans, Parkinson Disease, Lewy Bodies, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Parkinson’s disease: genetics and pathogenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks